Medically reviewed by Dr Sin Yong · Last reviewed · 20 min read · Doctor-performed, never delegated · Jump to questions
Dr Sin Yong · MBBS (NUS) · MRCS (Edin) · MSc Aesthetic Medicine with Distinction (Queen Mary, London) · MSc Practical Dermatology (Cardiff) · International KOL
Profhilo is a stabilised hybrid cooperative complex of high- and low-molecular-weight hyaluronic acid, injected at defined anatomical points to act on the skin itself rather than to add volume — assessed and placed by Dr Sin Yong at Orchard Road, Singapore.
Profhilo in Singapore is a stabilised hybrid cooperative complex of high- and low-molecular-weight hyaluronic acid, made by IBSA and injected at defined points to act on the skin itself. It is bio-remodelling, not a dermal filler, so it adds no volume or projection.
Also called: bio-remodelling hyaluronic acid, 逆时针, プロファイロ
Profhilo is an injectable preparation of hyaluronic acid, but it belongs to a different category from the hyaluronic acid fillers most people have heard of. It contains two populations of hyaluronic acid — one of high molecular weight, one of low — combined into what the manufacturer calls a hybrid cooperative complex, under the trade name NAHYCO. A 2 mL syringe carries 32 mg of each.
The distinction that matters clinically is the absence of a chemical crosslinker. Conventional hyaluronic acid fillers are crosslinked, usually with BDDE, so that the gel resists degradation and holds a shape under the skin. That is what allows a filler to project a chin or support a cheek. Profhilo is stabilised by a thermal process instead, and holds no shape at all. Injected, it spreads.

So the two products answer different questions. A filler answers where is volume missing. Profhilo answers how is this skin behaving.
This is the single most common misunderstanding, and it is worth being blunt about, because it is the reason people come away unimpressed.
If the complaint is a flat midface, a receded chin or a deep nasolabial fold driven by volume loss, Profhilo will not address it. Those are structural problems and they need something that holds structure — a crosslinked filler, or in some cases a different approach entirely. Profhilo placed into that situation will not produce the change the patient came for, and no amount of it will.
Where it is the right tool is the opposite situation: skin that has lost quality rather than volume. Crepiness. A dull, thin, poorly hydrated surface. Fine lines that sit on the skin rather than in the underlying shape. Necks and the backs of hands, where there is little to volumise and a great deal of surface change.
A sensible consultation separates those two things before anything is injected. Volume restoration and bio-remodelling are not competing options; they answer different complaints, and a face often needs the first before the second is worth doing.
Profhilo is not injected across the face the way a mesotherapy cocktail is. It is placed at a defined set of points per side — the Bio Aesthetic Points, or BAP — and those positions were not chosen for convenience.
They were chosen for two reasons. The first is vascular safety: each point sits away from the major facial vessels, which matters for any injectable placed in the subcutaneous plane. The second is spread. Because the product is uncrosslinked and low in viscosity, it diffuses through the subcutaneous layer from the point of deposit, so a small number of correctly placed boluses can cover a region that would otherwise need many superficial punctures.
That property is also why the injection is given with a fine needle despite the relatively high hyaluronic acid concentration — the hybrid complex has markedly lower dynamic viscosity than high-molecular-weight hyaluronic acid alone.
“Profhilo is not a filler. It gives improvement to areas by giving hydration, nutrients, and elements that the skin likes.”
Dr Sin YongOn what bio-remodelling actually does
The manufacturer's protocol specifies a fixed set of Bio Aesthetic Points per side. As a default it is sound: the positions are chosen for vascular safety and for predictable spread, and they are the right starting point for anyone working without a detailed assessment of the face in front of them.
Dr Sin Yong treats that set as the safety framework rather than the whole plan. A fixed pattern treats every face as the same face, and faces are not the same. Where the midface has deflated, where the jawline has softened, where the asymmetry sits — those regions place the greatest mechanical demand on the skin, and they do not always coincide with the standard points.
So the technique he uses keeps the defined points and adds placement according to the shape of the individual face. The anatomical rules governing where an injectable may safely sit do not change. What changes is the map.
He also places it into scarred skin, which the standard protocol does not address. Scar tissue is organised differently from the skin around it and behaves differently, and treating it alongside the rest of the face is a deliberate part of the plan rather than an afterthought.
This is the part that does not transfer from a brochure. It is also why the same product, in different hands, is not the same treatment.
The laboratory work behind the product is reasonably well characterised, and it is worth separating what has been measured from what is claimed in marketing.
The foundational study, published in PLoS ONE in 2016, examined hybrid cooperative complexes against the individual hyaluronic acid weights in skin cell models. Two findings are relevant. First, durability: roughly 35% of the high-molecular-weight material remained after ten days of exposure to hyaluronidase, against under 10% for standard high-molecular-weight hyaluronic acid on its own. Second, cellular response: the complexes increased gene expression of collagen types I, III, IV and VII and of elastin relative to the individual components, with type III collagen expression in fibroblasts rising roughly twelve-fold.
Those are laboratory measurements of gene expression in cell models. They explain the proposed mechanism; they are not a statement of what any individual's skin will do. There is also an open-label study in Asian patients, which is the more relevant population for Singapore, and a body of review literature on hybrid cooperative complexes in aesthetic medicine. All are listed in the references below.
Profhilo Structura is searched for almost as often as Profhilo itself, and the two are routinely conflated. They are separate products from the same manufacturer.
Standard Profhilo is directed at skin quality through the mechanism described above. Structura carries more hyaluronic acid, 90 mg in 2 mL, and is placed by cannula into the superficial fat compartments of the lateral face, where it is directed at fat-compartment change rather than skin quality. It is still not a conventional crosslinked filler, and it does not replace filler where defined volume is needed. They answer different complaints, and a clinic offering one is not necessarily offering the other.
If you have been quoted for “Profhilo” without being told which, that is worth clarifying before you proceed.

It suits skin where the surface quality has changed but the underlying shape has not: crepey texture, loss of hydration and light reflectance, early fine lines, a neck that has begun to show horizontal lines without significant laxity.
It does not suit a face whose main problem is descent or volume loss. It does not tighten skin in the way an energy-based device does — if the complaint is jowling or a loose jawline, focused ultrasound or radiofrequency is the relevant category, not an injectable hyaluronic acid. See HIFU and the VF Lift – Vertical Facelift for that distinction.
It is also not the right first step in a face that has never been assessed. A good deal of disappointment with injectables comes from treating the layer that is easiest to reach rather than the layer that is causing the complaint.
The common findings after injection are those of any intradermal or subcutaneous injectable: small raised deposits at the injection points that settle, bruising, tenderness, and transient swelling. Because the product is placed as discrete boluses, visible blebs at the points immediately afterwards are expected rather than a complication.
The serious risks are the ones that attend any injectable placed near facial vasculature, which is the reason the injection points are specified rather than improvised, and the reason the injector's anatomical knowledge matters more than the product does.
Hyaluronic acid products, including uncrosslinked ones, are degraded by hyaluronidase. The practical consequence is that this is not a lifelong intervention and the skin returns to its own trajectory once the material is gone.
| Product or class | What it is | Where it is placed | Directed at | What it does not do |
|---|---|---|---|---|
| Profhilo | Uncrosslinked hybrid hyaluronic acid (32 mg high- and 32 mg low-molecular-weight in 2 mL), thermally stabilised, made by IBSA | The skin, from defined Bio Aesthetic Points on each side | Crepey texture, hydration and early fine lines | Add volume, hold a contour or lift |
| Profhilo Structura | A separate IBSA product: 90 mg of hybrid hyaluronic acid in 2 mL | Superficial fat compartments of the lateral face, placed by cannula | Fat-compartment change in the lateral cheek and preauricular area | Replace filler for defined volume loss, lift heavy descent or remove skin |
| Hyaluronic acid skin boosters, such as Restylane Skinboosters | Soft, lightly stabilised or non-crosslinked hyaluronic acid | Many small injections into the dermis | Dull, dehydrated skin with fine surface lines | Restore volume, lift or treat pigment |
| Polynucleotides, such as Rejuran | Purified DNA fragments, usually from salmon | The dermis | Repair of texture, fine lines and thin under-eye skin | Add volume or lift; a fish allergy is raised first |
| Collagen biostimulators (Sculptra, Ellansé, Radiesse) | A resorbable scaffold that prompts the body's own collagen | Deeper planes, according to the product | Broader volume loss and firmness over a longer arc | Change surface hydration, or be dissolved with hyaluronidase |
Profhilo is not injected in anyone with a known allergy to hyaluronic acid or to any component of the product. It is deferred where there is active infection, inflammation, a cold sore or an acne flare at the injection points, and in pregnancy and while breastfeeding, where it has not been studied.
Other conditions call for caution rather than a refusal: autoimmune disease, a history of severe allergic reactions, a tendency to keloid scarring, and a bleeding tendency or blood-thinning medicines, which make bruising more likely. Where unknown or non-dissolvable filler has been placed in the area before, what is already in the tissue is established first, because layering over it complicates any later correction.
Profhilo is also the wrong choice for anyone whose main concern is volume loss, descent or a loose jawline, for the reasons set out above, and for anyone expecting a lift. Medical history and current medicines are reviewed, and suitability is decided at consultation.
The sequence below describes phases, not a timetable: how quickly each passes depends on the settings used, the area and the person, and is discussed at consultation.
People hoping to correct volume loss, a flat midface or a receded chin tend to respond poorly, because Profhilo is a skin quality treatment and the wrong tool for structure.
The fee depends on the areas treated, such as face, neck or hands, the syringes needed to cover them, whether placement is extended beyond the standard points to suit your face shape, and whether it is combined with another treatment such as a filler. The plan is set after assessment. A written quote is given at consultation, and the consultation also decides whether Profhilo is advised at all, or whether a filler or a different approach would suit your concern better.
How quotes work at this practice: how we quote.
It is an uncrosslinked hyaluronic acid preparation that spreads, adds no projection and answers skin quality rather than shape.
Structura is a separate IBSA product aimed at structural support, so the two are assessed and chosen differently.
These four are often quoted as if they were interchangeable, and they are not. The useful way to separate them is by the job each is built to do and by whether it is designed to spread or to stay put. Profhilo and hyaluronic acid skin boosters are directed at the quality of the skin. Profhilo Structura is a separate product, placed deeper in the lateral fat compartments. A dermal filler is cross-linked so that it holds a shape. The table sets them side by side. If you have been quoted for any of these by name alone, ask which product it is, where it is placed and what it is meant to change, because the answers decide what the treatment can and cannot do.
| Option | Built to | Spreads or stays put | Where it is placed | What it does not do |
|---|---|---|---|---|
| Profhilo | Act on the skin itself, using a stabilised hybrid hyaluronic acid complex | Spreads through the tissue from each point | The skin, from defined Bio Aesthetic Points | Add volume, hold a contour or lift |
| Hyaluronic acid skin boosters | Hydrate the dermis with lightly stabilised or non-crosslinked hyaluronic acid | Hydrates where it is placed | Many small injections into the dermis | Restore volume, lift or treat pigment |
| Profhilo Structura | Address change in the fat compartments of the lateral face | Placed by cannula as a separate product | Superficial fat compartments of the lateral face | Replace filler where defined volume is needed |
| Dermal filler (cross-linked hyaluronic acid) | Add volume or hold a contour | Stays where placed, built to resist spread | Planes chosen by the area being treated | Act on skin quality as its main job |
The modified BAP starts from the standard pattern and does not discard it. The manufacturer's Bio Aesthetic Points are defined positions, chosen for vascular safety and for how the product spreads, and Dr Sin Yong keeps them as the safety frame. Before treatment the skin is examined in good light, at rest and in movement, and pinched to see how it recoils. The points are marked against the anatomy examined, and whether every standard point is used is decided at that examination. The rules for where an injectable may safely sit are not relaxed because a plan has been customised.
Dr Sin Yong treats the standard set as the safety framework rather than the whole plan, and on top of that frame placement is added according to the shape of the individual face. A fixed pattern treats every face as the same face, so the regions that matter on yours, such as where the midface has deflated, where the jawline has softened or where an asymmetry sits, are looked at and included in the map. The map changes; the anatomical rules do not. This describes what is done and where the injections go, drawn up at the examination for the face in front of him. It is not a prediction of what any one face will do.
The third difference is scarred skin, which the standard protocol does not address. Scar tissue is organised differently from the skin around it and behaves differently, so it is assessed as its own area when the plan is drawn up. Dr Sin Yong places Profhilo into scarred skin as a deliberate part of the plan, alongside the rest of the face rather than as an afterthought. Whether that suits a particular scar is decided at consultation, and active infection or inflamed skin at the entry points is a reason to wait.
Whether Profhilo is worth it depends on what you hope it will change, and that is a question about the problem rather than the product. It is considered for skin whose surface quality has changed while the underlying shape has not: crepey texture, dullness, loss of hydration and early fine lines, including on the neck and hands. People who understand that it acts on the skin itself, and that it is a doctor-assessed injectable plan, are the ones for whom the decision makes sense. Cost follows the plan and is set out in writing at consultation, after assessment, so there is no figure to quote here.
It disappoints when the expectation is something it was never built to do. It adds no volume or projection, so a hollow cheek, a flat bridge or a receded chin is not its territory. It does not tighten skin the way an energy-based treatment does, so jowling and a loose jawline are better assessed for focused ultrasound or radiofrequency. It does not treat pigment or change pore size, and because hyaluronic acid is broken down by hyaluronidase it is not a lifelong intervention. An examination before injection separates skin quality from volume and from descent, and sometimes the honest advice is that Profhilo is not the right first step.
Question not answered here? Ask on WhatsApp, use the enquiry form, or browse 100 questions patients ask.
Stellavato A, Corsuto L, D'Agostino A, et al. Hyaluronan hybrid cooperative complexes as a novel frontier for cellular bioprocesses re-activation. PLoS ONE 2016. source
Efficacy and tolerability of stable hybrid cooperative complexes of high- and low-molecular weight hyaluronic acid in Asian patients: an open-label study. source
Hybrid cooperative complexes of low- and high-molecular-weight hyaluronic acid in aesthetic medicine. source
Health Sciences Authority. Infosearch — register of health products and medical devices approved for supply in Singapore. source
Singapore Medical Council. Guidelines on Aesthetic Practices for Doctors, 2016 Edition. source
Medically reviewed by Dr Sin Yong, MBBS (NUS), MRCS (Edinburgh) · Last updated 7 October 2026 · Editorial policy
Whether bio-remodelling is the right answer depends on whether the complaint is skin quality or lost volume. Dr Sin Yong assesses that first.
Arrange a consultation